Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

被引:46
|
作者
Kantoff, PW
Halabi, S
Farmer, DA
Hayes, DF
Vogelzang, NA
Small, EJ
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[2] Duke Univ, Med Ctr, Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA
[3] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1200/JCO.2001.19.12.3025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). Patients and Methods: Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR. Results: RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival far those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P = .004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information. Conclusion: RT-PCR for PSA predicts survival duration in a population of men with HRPC. J Clin Oncol 19:3025-3028. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:3025 / 3028
页数:4
相关论文
共 50 条
  • [41] Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy
    Thomas, J
    Gupta, M
    Grasso, Y
    Reddy, CA
    Heston, WD
    Zippe, C
    Dreicer, R
    Kupelian, PA
    Brainard, J
    Levin, HS
    Klein, EA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3213 - 3218
  • [42] External beam radiotherapy for clinically localized hormone-refractory prostate cancer: Clinical significance of nadir prostate-specific antigen within 12 months
    Ogawa, K.
    Nakamura, K.
    Sasaki, T.
    Onishi, H.
    Koizumi, M.
    Shioyama, Y.
    Araya, M.
    Okamoto, A.
    Mitsumori, M.
    Teshima, T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S55 - S56
  • [43] Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma
    Fujikawa, K
    Matsui, Y
    Fukuzawa, S
    Takeuchi, H
    [J]. EUROPEAN UROLOGY, 2000, 37 (02) : 218 - 222
  • [44] Reverse transcriptase-polymerase chain reaction assays for prostate cancer
    Olsson, CA
    deVries, GM
    Buttyan, R
    Katz, AE
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) : 367 - &
  • [45] Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer
    Perambakam, S
    Xue, BH
    Sosman, JA
    Peace, DJ
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (05) : 263 - 270
  • [46] Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer
    Supriya Perambakam
    Bao-Hua Xue
    Jeffrey A. Sosman
    David J. Peace
    [J]. Cancer Immunology, Immunotherapy, 2002, 51 : 263 - 270
  • [47] Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
    Collette, Laurence
    Buyse, Marc
    Burzykowski, Tomasz
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5673 - 5674
  • [48] Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
    Oudard, S.
    Banu, E.
    Scotte, F.
    Banu, A.
    Medioni, J.
    Beuzeboc, P.
    Joly, F.
    Ferrero, J. -M.
    Goldwasser, F.
    Andrieu, J. -M.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (11) : 1828 - 1833
  • [49] A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
    Pavlenko, M
    Roos, AK
    Lundqvist, A
    Palmborg, A
    Miller, AM
    Ozenci, V
    Bergman, B
    Egevad, L
    Hellström, M
    Kiessling, R
    Masucci, G
    Wersäll, P
    Nilsson, S
    Pisa, P
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (04) : 688 - 694
  • [50] Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer
    Figg, WD
    Ammerman, K
    Patronas, N
    Steinberg, SM
    Walls, RG
    Dawson, N
    Reed, E
    Sartor, O
    [J]. CANCER INVESTIGATION, 1996, 14 (06) : 513 - 517